# Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis

> **NCT01209208** · PHASE3 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 57 (actual)

## Conditions studied

- Lymphocytic Colitis

## Interventions

- **DRUG:** Budesonide
- **DRUG:** Mesalamine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01209208
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01209208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01209208, "Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01209208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*